Skip to main navigation

About Us
Our Science
Our Portfolio
Investors & Media
Careers
- Join Us
- Current Openings
Contact

News Releases

Year

Oct 14, 2021

Omega Therapeutics Announces Strategic Research Collaboration with Stanford University School of Medicine

Sep 27, 2021

Omega Therapeutics to Present at the Chardan Virtual 5th Annual Genetic Medicines Conference

Sep 10, 2021

Omega Therapeutics Reports Second Quarter 2021 Financial Results and Outlines Key Corporate Objectives

Jul 29, 2021

Omega Therapeutics Announces Pricing of Initial Public Offering

Jun 23, 2021

Omega Therapeutics Expands Board of Directors with Appointment of Luke Beshar

May 20, 2021

Omega Therapeutics Strengthens Board of Directors with Appointment of R&D Veteran Elliott M. Levy, M.D.

Mar 30, 2021

Omega Therapeutics to Advance Pipeline and Platform Development with $126 Million in Additional Financing

Jan 13, 2021

Omega Therapeutics Announces the Industry’s First Programmable Epigenetic Medicine in Development and 2021 Priorities

Jan 06, 2021

Omega Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

Site - Nav - Investors & Media

Corporate Profile
News & Events
- News Releases
- Events & Presentations
Stock Information
Corporate Governance
Financials & Filings
- SEC Filings
Investor Resources

Investor & Media Contact

Argot Partners
212-600-1902
ArgotOmega@argotpartners.com

Site - Investor Tools

Print Page

Email Alerts

RSS Feeds

Contact IR

Search

Home
About Us
Our Science
Our Portfolio
Investors & Media
Careers
Contact Us

20 Acorn Park Drive
Cambridge, MA 02140

ArgotOmega@argotpartners.com

© Omega Therapeutics, Inc. 2021 All Rights Reserved.
All other trademarks referenced herein are properties of their respective owners.

Terms of use

Privacy Policy